Implementation of a universal analytical method in early-stage development of human antibody therapeutics: Application to pharmacokinetic assessment for candidate selection

Bioanalysis

Volumn 4, Issue 19, 2012, Pages 2357-2365

  Shih, Judy Y ^a   Patel, Vimal ^a   Watson, Andrew ^a   Hager, Todd ^a   Luan, Peng ^a   Salimi Moosavi, Hossein ^a   Ma, Mark ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DRUG ANTIBODY; HUMAN MONOCLONAL ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; REAGENT;

ANALYSIS; ANALYTIC METHOD; ANIMAL TISSUE; ANTI HUMAN IGG FC IMMUNOASSAY; ARTICLE; ASSAY; BIOANALYSIS; COLORIMETRY; CONTROLLED STUDY; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; IMMUNOASSAY; IN VIVO STUDY; INTERMETHOD COMPARISON; MICROFLUIDICS; NONHUMAN; QUANTITATIVE ANALYSIS; SAMPLE; SINGLE DRUG DOSE; STANDARDIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; HORSES; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MICE; MICROFLUIDICS; PRIMATES; QUALITY CONTROL; RATS; SWINE;

EID: 84867957593     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.201     Document Type: Article

References (10)

1. Winheim S, Walser A, Kania M. Development and qualification of a generic igg quantification assay using surface plasmon resonance. BioProcess Int. 7(6), 36-42 (2009).
2. Dodge R, Daus C, Yaskanin D. Challenges in developing antidrug antibody screening assays. Bioanalysis 1, 699-704 (2009).
3. Stubenrauch K, Wessels U, Essig U, Vogel R, Schleypen J. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. J. Pharm. Biomed. Anal. 52, 249-254 (2010).
4. Yang J, Ng C, Lowman H, Chestnut R et al. Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a generic immunoglobulin pharmacokinetic (GRIP) assay. J. Immunol. Methods 335, 8-20 (2008).
5. Stubenrauch K, Wessels U, Lenz H. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates. J. Pharm. Biomed. Anal. 49, 1003-1008 (2009).
6. Mora J, Obenauer-Kutner L, Patel V. Application of the Gyrolab™ platform to ligand-binding assays: a user's perspective. Bioanalysis 2, 1711-1715 (2010).
7. Roman J, Qiu J, Dornadula G, Hamuro L, Bakhtiar R, Verch T. Application of miniaturized immunoassay to discovery pharmacokinetic bioanalysis. J. Pharmacol. Toxicol. Methods 63, 227-235 (2011).
8. Hermanson GT. Bioconjugate Techniques. Academic Press, San Diego, CA, USA, 377-380 (1996).
9. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macro-molecules. Pharm. Res. 20, 1885-1900 (2003).
10. Hall M, Gegg C, Walker K et al. Ligand-binding mass spectrometry to study bio-transformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor. AAPS J. 12, 576-585 (2010).